论文部分内容阅读
目的 观察活血与扶正活血中药联合放射治疗鼻咽癌的远期疗效。方法９８例首程放疗的鼻咽癌患者随机分成三组，Ｉ组３１例采用单纯放射治疗，Ⅱ组３３例联合活血汤治疗，Ⅲ组３４例联合扶正活血汤治疗。观察治疗前后患者症状、瘤体变化及细胞免疫功能，随访５年以上。结果 三组近期有效率差异无显著性意义（Ｐ＞０．０５）。毒副反应Ⅰ组明显高于Ⅱ、Ⅲ组（Ｐ＜０．０５）。５年生存率三组依次为３５．４８％、５１．５２％、６１．７０％，Ｉ组明显低于后两组（Ｐ＜０．０１）。远处转移率三组依次为１９．３５％、２７．２７％和１１．７６％，Ⅱ组与 Ⅰ、Ⅲ组比较差异有显著性意义（Ｐ＜０．０５）。治疗结束２个月后Ⅱ组ＣＤ３、ＣＤ４及ＮＫ细胞活性明显低于Ⅰ、Ⅲ组（Ｐ＜０．０５）。结论 扶正活血中药联合放射治疗能明显提高鼻咽癌患者远期生存率，而单纯活血药物有可能增加远处转移。
Objective To observe the long-term curative effect of combining traditional Chinese medicine and promoting blood circulation with traditional Chinese medicine on radiotherapy of nasopharyngeal carcinoma. Methods A total of 98 patients with nasopharyngeal carcinoma treated with first-line radiotherapy were randomly divided into three groups: 31 cases in group I received radiotherapy alone, 33 cases in group Ⅱ combined with Huoxue Decoction, and 34 cases in group Ⅲ combined with Fuzhenghuoxue Decoction. Observed before and after treatment of patients with symptoms, tumor changes and cellular immune function, follow-up more than 5 years. The results of the three groups no significant difference in the recent efficiency (P> 0.05). Toxicity in group Ⅰ was significantly higher than in group Ⅱ and Ⅲ (P <0.05). The 5-year survival rates were 35.48%, 51.52% and 61.70% in the three groups, and the I group was significantly lower than the latter two groups (P <0.01). The distant metastasis rates of the three groups were 19.35%, 27.27% and 11.76%, respectively. There was significant difference between group Ⅱ and groups Ⅰ and Ⅲ (P <0.05). After 2 months of treatment, the activity of CD3, CD4 and NK cells in group Ⅱ were significantly lower than those in group Ⅰ and Ⅲ (P <0.05). Conclusion Fuzheng Huoxue combined with radiotherapy can significantly improve the long-term survival rate of patients with nasopharyngeal carcinoma, and pure blood drug may increase the distant metastasis.